Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05766813 · ClinicalTrials.gov registry record · Phase 2

Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease

A Phase 2 study of Parkinson Disease, sponsored by Intra-Cellular Therapies.

Recruiting
Registry status
Phase 2
Development phase
132
Enrollment target
20
Study locations

NCT05766813 is a Phase 2 study of Parkinson Disease that is actively recruiting participants, run by Intra-Cellular Therapies. The registered enrollment target is 132 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05766813, a Phase 2 study of Parkinson Disease, is actively recruiting participants, sponsored by Intra-Cellular Therapies.

RECRUITING
Registry status
Phase 2
Development phase
132 participants
Enrollment target
20
Study locations

Study Summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a diagnosis of Parkinson's Disease consistent with the UK Parkinson's Disease Society (UKPDS) Brain Bank diagnostic criteria, who are experiencing wearing off symptoms and levodopa-induced dyskinesia.

Conditions Studied

Parkinson Disease

Interventions

  • DRUG Placebo
  • DRUG Lenrispodun

Study Locations (20)

Florida

  • Clinical Site - Altamonte Springs
  • Clinical Site - Boca Raton
  • Clinical Site - Coral Springs
  • Clinical Site - Hallandale
  • Clinical Site - Maitland
  • Clinical Site - Miami
  • Clinical Site - Ocala
  • Clinical Site - Orlando
  • Clinical Site - Orlando
  • Clinical Site - Port Orange
  • Clinical Site - Tampa

Arizona

  • Clinical Site - Phoenix
  • Clinical Site - Scottsdale

California

  • Clinical Site - Irvine
  • Clinical Site - Loma Linda

Georgia

  • Clinical Site - Augusta
  • Clinical Site - Decatur

Kansas

  • Clinical Site - Kansas City

Michigan

  • Clinical Site - Farmington Hills

Minnesota

  • Clinical Site - Golden Valley

Trial Details

FieldValue
Enrollment Target 132 participants
Start Date 2023-03-13
Est. Completion 2025-10
Phase Phase 2

Sponsor

Intra-Cellular Therapies

37 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05766813

The ClinicalTrials.gov registry entry for NCT05766813 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The listed sponsor is Intra-Cellular Therapies, which has 37 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05766813 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT05766813 about?

NCT05766813 is a clinical study titled "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease". This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a diagnosis of Parkinson's Disease consistent with the UK Parkinson's Disease Society (UKPDS) Brain Bank diagnostic criteria, who are experiencing wearing off symptoms and levodopa-...

What is the current status of trial NCT05766813?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 132 participants. The study started on 2023-03-13. Estimated completion is 2025-10.

What conditions does trial NCT05766813 study?

This clinical trial studies the following conditions: Parkinson Disease.

What interventions are being tested in trial NCT05766813?

The interventions under investigation include: Placebo (DRUG), Lenrispodun (DRUG).

Who is sponsoring clinical trial NCT05766813?

This trial is sponsored by Intra-Cellular Therapies, which has 37 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05766813 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson Disease

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.